| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c72f4838ea9e73b698d416f14ce5cbf7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 |
| filingDate |
1995-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b171b737442ce5140b33e923484f394
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d38c2e0a12682e5d0c12806267d6413
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b8ff2a27d7065e0af2d4acd7f7b21b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c202dd804f9504dfd63eda1d6b53808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8507fa3eeb8cd5b264bc47bb67e3149 |
| publicationDate |
1995-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2187781-A1 |
| titleOfInvention |
Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction |
| abstract |
Methods for diagnosis or treatment of a disease or condition in an organism characterized by an abnormal level of interaction between: (a) a BLM domain and its natural binding partner; or (b) an EGF receptor and an EGF ligand is described. The disease or condition may also be characterized by an abnormality in a signal transduction pathway, wherein the pathway contains a protein with a BLM domain or an EGF receptor. The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complexes formed between the individual molecules. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features a peptide comprising, consisting or consisting essentially of a BLM domain or EGF receptor domains 1 or 3. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7935784-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7939080-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7608269-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7393823-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7396810-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7625859-B1 |
| priorityDate |
1994-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |